Heron Therapeutics Inc
HRTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$55.69M
Close$
$3.67
1070.5% upside
Current Fair Value
1070.5% upsideUndervalued by 1070.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $55.69 Million |
|---|---|
| Enterprise Value | $183.32 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.12 |
| Beta | 1.62 |
| Outstanding Shares | 190,335,000 |
Return
| Return on Equity | -492.89% |
|---|---|
| Return on Assets | -13.50% |
| Return on Invested Capital | -10.18% |
Valuation & Multiples
| P/E Ratio | -1.57 |
|---|---|
| PEG | -1.2 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.21 |
| Enterprise Value to EBIT | -11.25 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.81 |
| Debt to Equity | 21.48 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
$42.19 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.03
Average shareholder expectationRevenue Estimate
$37.50 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.8726▼ 2.61% |
|---|---|
| Total Calls | 1,138,400▲ 1.26% |
| Total Puts | 2,131,800▼ 0.13% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 71.05%▼ 11.67% |
|---|---|
| Total Invested | $57.92M▼ 53.90% |
| Investors Holding | 170▼ 3.00% |
ESG Score
No data
About Heron Therapeutics Inc
CEO: Barry Quart